Kwangdong clinical study approved for KD501, Arzheimer drug.

Published: 2007-07-25 06:56:00

Updated: 2007-07-25 06:56:00

Kwangdong announced on July 23 that a clinical phase II study protocol for KD501, an Arzheimer disease therapy of natural origin, was approved by the KFDA.

KD501 is a new anti-psychotic drug with natural origin jointly developed by Kwangdong Research teams in association with Prof. Kim Young-...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK